SCHEMBL200996

SCHEMBL200996

CCC(CN)(C(C)C)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8366945 0.84
SCHEMBL9510919 0.83 ALDH1A1 (0.35) CYP2D6ALDH1A1
SCHEMBL16286962 0.79 TSHR (0.33) TSHRTDP1
SCHEMBL2402939 0.77
SCHEMBL23257074 0.75 ALDH1A1 (0.30) ALDH1A1
SCHEMBL5932813 0.73
SCHEMBL2409442 0.73 TSHR (0.37) TSHRTDP1
SCHEMBL18769387 0.73
SCHEMBL21690219 0.71 TSHR (0.33) TSHR
SCHEMBL23425128 0.69 CYP2D6 (0.32) CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240358707-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2024-10-31 US disclosed
US-20240317756-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2024-09-26 US disclosed
US-20220213106-A1 Inhibitors of Bruton's Tyrosine Kinase PHARMACYCLICS LLC (US) 2022-07-07 US disclosed
US-20220008424-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2022-01-13 US disclosed
US-20200289515-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS, INC. 2020-09-17 US disclosed
US-20200276199-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS LLC 2020-09-03 US disclosed
US-20200108072-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. 2020-04-09 US disclosed
US-20200055859-A1 INHIBITORS OF BRUTONS TYROSINE KINASE PHARMACYCLICS LLC (US) 2020-02-20 US disclosed
US-20180193345-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS PHARMACYCLICS LLC 2018-07-12 US disclosed
EP-3311818-A2 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS Pharmacyclics, LLC (US) 2018-04-25 EP disclosed
US-6017496-A ELECTROMAGNETICALLY TAGGED BY PROGRAMMING THE MEMORY WITH DATA CORRESPONDING TO IDENTIFYING INFORMATION OR CAN BE TAGGED BY IMPRINTING THE MATRIX WITH IDENTIFYING INFORMATION; DATA STORAGE; SLEEVE ATTACHED TO A CONTAINER IRORI (US) 2000-01-25 US disclosed
WO-1999065870-A2 SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE VERTEX PHARMACEUTICALS INCORPORATED (US) 1999-12-23 WO disclosed
US-5961923-A THE MATRIX MATERIALS ARE THOSE THAT ARE USED IN AS SUPPORTS IN SOLID PHASE CHEMICAL AND BIOCHEMICAL SYNTHESES, IMMUNOASSAYS AND HYBRIDIZATION REACTIONS. IRORI (US) 1999-10-05 US disclosed
US-5874214-A USEFUL FOR IDENTIFICATION, TRACKING AND CATEGORIZATION OF COMPONENTS OF COMPLEX MIXTURES OF DIVERSE MOLECULES; DRUG DELIVERY IRORI (US) 1999-02-23 US disclosed
WO-1997049653-A9 SOLID PHASE TYRPHOSTIN LIBRARY LINKED TO MATRICES WITH MEMORIES 1998-04-16 WO disclosed
WO-1997012680-A9 MATRICES WITH MEMORIES, SENSORS WITH MEMORIES AND USES THEREOF 1998-02-26 WO disclosed
EP-0822861-A1 REMOTELY PROGRAMMABLE MATRICES WITH MEMORIES AND USES THEREOF Irori (US) 1998-02-11 EP disclosed
WO-1997049653-A2 SOLID PHASE TYRPHOSTIN LIBRARY LINKED TO MATRICES WITH MEMORIES IRORI (US) 1997-12-31 WO disclosed
WO-1996036436-A1 REMOTELY PROGRAMMABLE MATRICES WITH MEMORIES AND USES THEREOF IRORI (US) 1996-11-21 WO disclosed
US-5189042-A Treating autoimmune diseases, preventing transplant rejection MERCK & CO. INC. (US) 1993-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200108072-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LCK, LYN CYP2D6 2442/4885TSHR 3088/4885TDP1 325/4885
US-20220213106-A1 Inhibitors of Bruton's Tyrosine Kinase ABL1, BTK, ABL2 CYP2D6 4195/4885TSHR 3200/4885TDP1 284/4885
US-20220008424-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LCK, LYN CYP2D6 2442/4885TSHR 3088/4885TDP1 325/4885
US-20180193345-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN CYP2D6 4330/4885TSHR 2102/4885TDP1 348/4885
US-20240358707-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LCK, LYN CYP2D6 2442/4885TSHR 3088/4885TDP1 325/4885
US-20200289515-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN CYP2D6 4330/4885TSHR 2102/4885TDP1 348/4885
US-20240317756-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 CYP2D6 4195/4885TSHR 3200/4885TDP1 284/4885
US-20200055859-A1 INHIBITORS OF BRUTONS TYROSINE KINASE ABL1, BTK, ABL2 CYP2D6 4241/4885TSHR 2734/4885TDP1 365/4885
US-20200276199-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS BTK, ABL1, LYN CYP2D6 4330/4885TSHR 2102/4885TDP1 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.